7 research outputs found

    A National Study of State Policy for Fostering Gifted Program Evaluation: Content Analysis and Recommendation for Policy Development

    No full text
    Individual state policy plays a pivotal role in the policies and practices related to gifted education at the local level. While little is known about the frequency with which local school personnel evaluate their gifted and talented programs, the policy documents of 31 states include language to suggest that schools should conduct evaluations of their gifted and talented programs. In this study, a content analysis of high-level state policy documents was conducted to identify three main policy approaches for fostering local gifted program evaluation: (a) policies to initiate the development of sub-policies to guide program evaluation practice, (b) policies directly calling for schools to evaluate their gifted programs, and (c) policies that designate technical assistance services to support program evaluations. Findings from the content analysis also indicate that the majority of these policies lack the comprehensiveness Trochim describes in his theoretical work, the Evaluation Policy Wheel (EPW). For example, of the eight EPW components described as part of comprehensive evaluation policy, the most comprehensive of all the state evaluation policies examined in this study contained only 5 of the 8 policy components. In fact, the majority of the state policies (n = 20) contained less than 30% of the policy components from the EPW. ^ An illustrative case example was also included in this study to explore how researchers and policymakers might examine the alignment of state evaluation policy with other influential sources of program evaluation advice. In this study, the policies from one state were explored for their alignment with Patton\u27s Utilization-Focused Evaluation, the utilization strand from the Joint Committee\u27s Program Evaluation Standards, and the National Association for Gifted Children\u27s (NAGC) PreK-Grade 12 Gifted Programming Standards. This process resulted in an analytic framework through which evaluation policy may be examined for consistency with best practices recommendations, aiding in the illumination of sources of consistency as well as areas for further policy development or improvement.

    Determinants and Consequences of Corporate Tax Avoidance

    No full text

    Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort

    No full text
    Individuals with rare kidney diseases account for 5-10% of people with chronic kidney disease, but constitute more than 25% of patients receiving kidney replacement therapy. The National Registry of Rare Kidney Diseases (RaDaR) gathers longitudinal data from patients with these conditions, which we used to study disease progression and outcomes of death and kidney failure.People aged 0-96 years living with 28 types of rare kidney diseases were recruited from 108 UK renal care facilities. The primary outcomes were cumulative incidence of mortality and kidney failure in individuals with rare kidney diseases, which were calculated and compared with that of unselected patients with chronic kidney disease. Cumulative incidence and Kaplan-Meier survival estimates were calculated for the following outcomes: median age at kidney failure; median age at death; time from start of dialysis to death; and time from diagnosis to estimated glomerular filtration rate (eGFR) thresholds, allowing calculation of time from last eGFR of 75 mL/min per 1·73 m2 or more to first eGFR of less than 30 mL/min per 1·73 m2 (the therapeutic trial window).Between Jan 18, 2010, and July 25, 2022, 27 285 participants were recruited to RaDaR. Median follow-up time from diagnosis was 9·6 years (IQR 5·9-16·7). RaDaR participants had significantly higher 5-year cumulative incidence of kidney failure than 2·81 million UK patients with all-cause chronic kidney disease (28% vs 1%; p Background Methods Findings Interpretation Funding</p

    31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

    No full text
    corecore